

Special Issue

New Advances in Metastatic Prostate Cancer

Message from the Guest Editor

The treatment of metastatic prostate cancer has evolved enormously within the last decade. The outcome data of recent clinical trials are encouraging in that prognosis of metastatic prostate cancer can be shifted from a life-threatening to chronic disease. However, novel resistance mechanisms complicate tumor control in advanced stages. In particular, treatment-related anaplastic tumors with neuroendocrine features pose a challenge for urooncologists. Therefore, it is of major importance to explore the genetic alterations leading to treatment resistance and to seek out potential targets for specific treatment to regain tumor control. In this Special Issue, experts in this field will review the current approaches to the management of patients with metastatic prostate cancer.

Guest Editor

Prof. Dr. Christian Thomas

Department of Urology, University Hospital Carl Gustav Carus,
Technical University of Dresden, Dresden, Germany

Deadline for manuscript submissions

closed (20 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/73390

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)